FDA Endorses, Pushes for Abuse-Resistant Opioid Formulations: Transition to Disrupt Pain Market
The opioid market is dominated by non-tamper resistant formulations (TRFs), but the Food and Drug Administration’s (FDA’s) promotion of TRF therapies could well result in the departure of non-TRF therapies from the market and shake up its structure.
Purdue Pharma’s Oxycontin is the only opioid pain treatment among the top 50 selling pharmaceutical products in the US. Unless FDA mandates TRF therapies, further genericization and lack of novel mechanism of actions (MOAs) will ensure opioids are unrepresented in the top 50 by 2018. Despite these debilitating trends, large opportunity remains for tamper resistant technologies, as well as combination therapies to minimise side-effects from opioid products.
New analysis from Frost & Sullivan’s "Competitive Analysis of the Global Opioid Therapeutics Market" finds, with 25 million Americans suffering from moderate-to-severe chronic pain that interferes with their daily lives, orally delivered pain products will continue to dominate the market. Purdue’s Oxycontin leads this category, generating $2.77 billion in sales in 2012. The transdermal category was led by Johnson & Johnson’s Duragesic patch for cancer-induced pain and Endo’s Lidoderm patch for chronic pain.
FDA’s push for abuse-deterrent formulations will also spell a boom for extended-release opioids. So far, in spite of the continued development of extended-release formulations, immediate-release formulations have dominated the market with 91% of the market share. This is partly a result of the recent requirement for a risk evaluation mitigation strategy (REMS) for extended-release formulations. However, with FDA favoring TRF therapies, extended-release drugs will find greater favour among drug developers.
“Another outcome of FDA’s endorsement of TRFs is the flooding of the pain therapy pipeline with new TRF opioid-based therapies,” said Frost & Sullivan Life Sciences Global Research Director Jennifer Lazar Brice. “In this scenario, Pfizer has significant opportunity to grow, with its broad pipeline of oral (TRFs), transdermals and IV candidates.”
As opioids are the mainstay of pain treatment, there is a substantial market for a therapy for opioid-induced constipation. Nektar Therapeutics’ NKTR-118, a Phase III candidate to treat the issue, will be of particular interest.
Companies that can develop a novel, non-opioid MOA therapy will particularly stand to gain in this market. Healthcare providers will be keenly watching the developments in calcitonin gene related peptide (CGRP)-targeted therapies.
“Overall, the future of the pain market is heavily dependent upon FDA’s decision to remove non-TRF generic therapies from the market,” noted Brice. “This move will create a huge opportunity for new TRF therapies to remain branded.”
"Competitive Analysis of the Global Opioid Therapeutics Market" is part of Frost & Sullivan’s newly repositioned Life Sciences Growth Partnership Service programme, which now includes the Competitive Intelligence research service. All therapeutic research services included in this subscription provide analyses and dashboards for competitive factors, clinical trials, timelines, M&As, products and vendors; as well as companies to watch, position-altering strategies, and market opportunities and predictions. The research also includes company and key opinion leader interviews, recruitment statuses, safety/efficacy analyses, market milestones, and best practices in the industry. This Competitive Intelligence enables companies to better position their sales and marketing strategy towards clinical development programmes and prioritisations.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance